



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARK
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/788280	2/15/2001	D.S. Burt	021984-00041045

EXAMINER	
K. Winkler	
ART UNIT	PAPER NUMBER
1648	12/15/2003

DATE MAILED:

INTERVIEW SUMMARY

All participants (applicant, applicant's representative, PTO personnel):

(1) Karen Dow (3) _____

(2) Ulrike Winkler (4) _____

Date of Interview 12/15/03

Type: ☒ Telephonic ☐ Televideo Conference ☐ Personal (copy is given to ☐ applicant ☐ applicant's representative).

Exhibit shown or demonstration conducted: ☐ Yes ☐ No If yes, brief description: _____

Agreement ☒ was reached. ☐ was not reached.

Claim(s) discussed: all pending

Identification of prior art discussed: NA

Description of the general nature of what was agreed to if an agreement was reached, or any other comments:

discussed proposed amendment faxed 11/26/2003 indicated that
claims limited to HA antigen would be allowable.
Applicants will fax new claims.

(A fuller description, if necessary, and a copy of the amendments, if available, which the examiner agreed would render the claims allowable must be attached. Also, where no copy of the amendments which would render the claims allowable is available, a summary thereof must be attached.)

☒ It is not necessary for applicant to provide a separate record of the substance of the interview.

Unless the paragraph above has been checked to indicate to the contrary. A FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION IS NOT WAIVED AND MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW.

Examiner Note: You must sign this form unless it is an attachment to another form.

[Handwritten Signature]



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARK
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/788280	02/15/2001	D.S. Burt	40532000600

EXAMINER
U. Winkler

ART UNIT	PAPER NUMBER
1648	23

DATE MAILED:

INTERVIEW SUMMARY

All participants (applicant, applicant's representative, PTO personnel):

- (1) Karen Dow (App Rep) (3) _____
(2) Ulrike Winkler (PTO) (4) _____

Date of Interview 11/19/03 ; 11/24/03

Type: ☒ Telephonic ☐ Televideo Conference ☐ Personal (copy is given to ☐ applicant ☐ applicant's representative).

Exhibit shown or demonstration conducted: ☐ Yes ☒ No If yes, brief description: _____

Agreement ☒ was reached. ☐ was not reached.

Claim(s) discussed: all pending

Identification of prior art discussed: NA

Description of the general nature of what was agreed to if an agreement was reached, or any other comments: _____

in prior office action indicated that the polypeptide-antigen formulation at 4:1 would be allowable. Applicant's have amended claims to read "greater than 1:1 formulation", prior 103 rejection indicated that optimizing formulation is within the skill of ordinary artisan the prior

(A fuller description, if necessary, and a copy of the amendments, if available, which the examiner agreed would render the claims allowable must be attached. Also, where no copy of the amendments which would render the claims allowable is available, a summary thereof must be attached.)

☐ It is not necessary for applicant to provide a separate record of the substance of the interview.

Unless the paragraph above has been checked to indicate to the contrary, A FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION IS NOT WAIVED AND MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW.

Examiner Note: You must sign this form unless it is an attachment to another form.

"greater than 1:1" would include as little as a single molecule which is within the experimental error set out in prior art. Hence applicant is given the option to limit claim to 4:1 or 8:1 formulation as set out in specification. Applicant's intend to submit a supplemental amendment setting out ratio of 2:1, 4:1 + 8:1 as found in spec that he